【摘要】 目的分别以HPLC指纹图谱的主成分保留率和急性肝损伤的药效模型为指标,评价绵茵陈提取液的大孔吸附树脂精制工艺的合理性。方法以HPLC指纹图谱的主峰保留率为指标,对绵茵陈提取液的精制工艺进行评价;建立CCl4致小鼠急性肝损伤模型,测定血清中谷丙转氨酶(ALT)、谷草转氨酶(AST),并观察肝组织病理学变化;进行小鼠灌胃给药的急性毒性实验,考察绵茵陈提取液精制前后口服给药的安全性。结果绵茵陈提取液精制前后的HPLC指纹图谱基本一致;绵茵陈提取液精制前后的保肝作用无显著差异;绵茵陈提取液精制前后均未发现明显的急性毒性反应。结论以HPLC指纹图谱和药效学实验相结合的评价方法,证实了绵茵陈提取液大孔吸附树脂精制工艺的合理性。更多还原

【Abstract】 Objective To evaluate the refinement process for extracting Herba Artemisiae Scopariae(HAS) with macroporous resin.Methods With reservation rate of main peak in the fingerprint as the index,the refinement process for extract of HAS was evaluated.The safety of oral administration of HAS extract before and after refinement process was evaluated by detecting serum levels of alanine aminotransferase(ALT) and aspartate aminotransferase(AST),observing the hepatic histopathological changes in mice model of CCl4-induced acute hepatic injury,and by mice acute toxicity experiment.Results The fingerprint of HAS extract before and after treatment was similar,the difference of their hepatoprotective effect was insignificant,and there was no obvious acute toxic reaction of HAS extract before and after refinement.Conclusion This experiment verified the rationality of the refinement process for extracting Herba Artemisiae Scopariae with macroporous resin by the method of pharmacodynamics combining with HPLC fingerprint.更多还原